芪苈强心胶囊联合无创通气治疗COPD合并肺源性心脏病的疗效

Efficacy of Qili Qiangxin Capsule Combined With Non-invasive Positive Pressure Ventilation in Treatment of COPD Patients With Pulmonary Heart Disease

目的 探讨芪苈强心胶囊联合无创正压通气在治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并慢性肺源性心脏病失代偿期患者中的疗效。方法 选取2018年1月—2021年6月在湖北省松滋市人民医院呼吸内科住院的COPD合并慢性肺源性心脏病失代偿期患者60例,其中随机数字法分为试验组30例,对照组30例,两组均给予小剂量利尿剂、无创正压呼吸机辅助通气、抗感染及解痉平喘等治疗,试验组另外给予芪苈强心胶囊口服,对照组根据指征选用可加用小剂量强心剂(选择西地兰或者地高辛),治疗开始前和结束后,分别检测患者的血气分析、超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、脑钠肽,治疗结束后对比两组疗效。结果 在治疗开始前,两组的年龄、血气分析、hs-CRP、脑钠肽等经统计学分析差异无统计学意义(P> 0.05);在治疗结束后,两组血气分析、脑钠肽经统计学分析差异有统计学意义(P <0.05),两组hs-CRP经统计学分析差异无统计学意义(P> 0.05)。结论 芪苈强心胶囊联合无创正压通气治疗COPD合并慢性肺源性心脏病失代偿期患者的疗效确切,有临床意义,可提供参考。

Objective To explore the efficacy of Qili Qiangxin capsule combined with non-invasive positive pressure ventilation in the treatment of chronic obstructive pulmonary disease(COPD)and decompensated chronic pulmonary heart disease.Methods 60patients with COPD and decompensated chronic pulmonary heart disease from January 2018 to June 2021 in Songzi People’s Hospital in Hubei were selected,among which 30 cases were randomly divided into the experimental group and 30 cases were in the control group.Both groups were given low-dose diuretic,non-invasive positive pressure ventilator assisted ventilation,anti-infection and spasmodic antiasthmatic treatment.Experimental group were given Qili Qiangxin capsule,control group according to the indication can be added with a small dose of cardiac agent(cedilanid or dioxin).Before and after the treatment,blood gas analysis,high-sensitivity C-reactive protein(hsCRP) and brain natriuretic peptide were measured,and the efficacy was judged after the treatment.Results Before the treatment,the age,blood gas analysis,hs-CRP and brain natriuretic peptide of the two groups was not statistically significant in statistical analysis(P > 0.05).After treatment,there were differences in blood gas analysis,D-dimer and brain natriuretic peptide between the two groups,and the differences were statistically significant(P 0.05).Conclusion Qili Qiangxin capsule combined with non-invasive positive pressure ventilation in the treatment of COPD and decompensated chronic pulmonary heart disease of patients with definite curative effect,clinical significance,worthy of clinical application.